FDA clears PD‑L1 test for ovarian cancer

Ovarian cancer treatment just picked up a new gatekeeper. The FDA approved Agilent’s PD‑L1 IHC 22C3 pharmDx as the companion diagnostic for Merck’s Keytruda in epithelial ovarian, fallopian tube, and primary peritoneal cancers, and it did that alongside a new Keytruda regimen in platinum-resistant disease. That sounds like a narrow lab update, but it is really a treatment-access story. If the tumor does not test the right way, the drug is not the indicated option. ### What actually got approved? The FDA approved pembrolizumab with paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer whose tumors express PD‑L1. At the same time, it approved PD‑L1 IHC 22C3 pharmDx, Code SK006, from Agilent as the companion diagnostic to identify those eligible patients. In plain English, the drug and the test moved together. ### What is a companion diagnostic? It is not just a helpful biomarker test. It is an FDA-regulated assay that sits inside the prescribing workflow for a specific drug. Doctors can still use judgment, but the approved label points to this exact test for this exact decision. That matters because oncology has plenty of PD‑L1 assays floating around, and they are not automatically interchangeable once the FDA names one. ### Why PD‑L1? PD‑L1 is a protein tumors can use to dampen immune attack. Keytruda blocks the PD‑1/PD‑L1 checkpoint, so the basic idea is straightforward — if a tumor shows PD‑L1 expression, it may be more likely to benefit. Here the FDA-cleared cutoff is a combined positive score, or CPS, of at least 1. That threshold is the practical line between eligible and ineligible patients under the label. ### Why is this a big deal in ovarian cancer? Because ovarian cancer has been a tough place for immunotherapy to break through. This approval is being framed as the first immuno-oncology approval in this disease setting, which is why the test matters so much. It is not just expanding an existing playbook from lung or gastric cancer. It is helping define a new one for a hard-to-treat group of patients with platinum-resistant disease. ### Which patients are we talking about? Not everyone with ovarian cancer. The approved use is for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after prior systemic therapy, and only when the tumor is PD‑L1 positive by the approved assay. That is a pretty specific slice of the population, but it is also a group with limited options and high unmet need. ### Why does the exact assay matter so much? Because once the FDA names Agilent’s 22C3 test as the companion diagnostic, labs and oncology practices have to think about validation, workflow, and access. A biomarker strategy is only useful if patients can actually get tested fast enough to make treatment decisions. That is why Labcorp’s recent national rollout matters too — it shows the commercial lab system is already building around the approval. ### Does this change the drug-diagnostic business model? Basically, yes. The approval tightens the link between Merck’s drug franchise and Agilent’s assay platform, and it reinforces a broader trend in oncology — drugs increasingly launch with a regulated testing pathway attached. That can drive demand for specific kits, specific scoring methods, and specific lab partnerships rather than a logistics more important. ### Bottom line? This was not just a diagnostic clearance. It was the FDA wiring a new ovarian cancer immunotherapy option directly to a named PD‑L1 test, which means the lab result is now part of the treatment itself.